Beijing, – A newly developed mRNA tuberculosis (TB) vaccine in China has entered clinical trials on Monday (March 24) at Beijing Chest Hospital. The vaccine could provide a new immunization option for people of all ages and effectively reduce TB infection and incidence rates.

Animal trials have shown that this new TB vaccine has more than 20 times the protective efficacy compared to the Bacillus Calmette-Guérin (BCG) vaccine and other foreign TB vaccines.

In the next phase, the research and development team will study immune response strategies, immunization methods, and related symptom patterns.

Additionally, the hospital has introduced an AI-powered diagnostic model and a rapid TB detection method using tongue swab samples. This AI diagnostic model can identify respiratory diseases, including TB, in the early stages non-invasively and can be utilized remotely.

Currently, the AI diagnostic model is still in the preclinical testing phase, while the rapid TB detection method is expected to be gradually rolled out across China starting in July.

Source:
WorldViewThaiNews